FunGen-xQTL Resources

GWASAD GWAS

Alzheimer's disease GWAS: Kunkle et al. 2019

SNP-level association summary statistics for Alzheimer’s disease (AD) from Kunkle et al. 2019 in Nature Genetics. Positions were converted from hg19 to hg38 with liftOver.
Cohort
AD GWAS
Modality
GWASGWAS
Lead analysts
Oluwatosin OlayinkaSelect a name to email them

Get the data

Controlled access. Request data access on the AD Knowledge Portal; you need a free account there. See How to get the data.

WhereIDAccessWhat you get
AD Knowledge Portalsyn69670625ControlledFiles described below
shell
pip install synapseclient
synapse login
synapse get -r syn69670625

Every AD Knowledge Portal folder that mentions this dataset 7 locations

Variant and gene summaries1
  • AD_loci_summary › AD_finemapping · syn69865805
    • AD_Kunkle_Stage1_2019.gwas.top_loci.bed.gz
xQTL and AD GWAS models6
  • AD_finemapping › susie_rss › batch{1..2} · syn77238945
    • AD_Kunkle_Stage1_2019.*.gwas_finemap.rds
  • AD_GWAS_models › AD_TWAS_association › batch1 · syn75427328Joint analysis of eQTL + pQTL; also listed on the other data type's pages
    • ROSMAP_eQTL_pQTL_AD_Kunkle_Stage1_2019.*.twas.tsv.gz
  • AD_xQTL_integration › AD_xQTL_colocalization_models › ROSMAP · syn74986543
    • ROSMAP.*.cb_xqtl_AD_Kunkle_Stage1_2019.rds
  • AD_xQTL_integration › AD_xQTL_colocalization_models › MSBB · syn74986553
    • MSBB.*.cb_xqtl_AD_Kunkle_Stage1_2019.rds
  • AD_xQTL_integration › AD_xQTL_colocalization_models › KNIGHT · syn74986587
    • KNIGHT.*.cb_xqtl_AD_Kunkle_Stage1_2019.rds
  • AD_xQTL_integration › AD_xQTL_colocalization_models › MiGA · syn74986600
    • MiGA.*.cb_xqtl_AD_Kunkle_Stage1_2019.rds

Folders and files whose names carry this dataset's cohort, data type and tissue (bulk and single-nucleus data kept apart), taken from the staging folder list. All AD Knowledge Portal folders lists everything.

Contact

Oluwatosin Olayinka

Source files

The original summary statistics (GRCh37) and a liftover to GRCh38 are held on the Columbia University (CU) cluster.

Path to SuSiE RSS Fine-mapping Objects

AD GWAS–xQTL Integration

AD GWAS–xQTL colocalization results (ColocBoost): syn69865816

AD GWAS–xQTL colocalization models: syn69670630

AD colocalization models (all GWAS studies): syn69670626

Integrated AD Gene-Level Summary

AD risk genes prioritized by xQTL + GVC: syn70095142

AD risk genes prioritized by xQTL + TWAS + GVC: syn70095143

Download source

The data are derived from the summary statistics of Kunkle et al..

File Schema

  • chromosome: chromosome ID
  • position: hg38 position (converted from hg19 with liftOver)
  • variant: variant ID in the form chr${chromosome}_${position}_${ref}_${alt}
  • alt: alternative effect allele
  • ref: reference allele
  • beta: SNP effect size
  • se: standard error of beta
  • pvalue: p-value of beta
  1. Summary statistics preprocessing: https://github.com/floutt/brain-xqtl-analysis/blob/main/analysis/Zhang_BU/susie_rss/summary_stat_qc_all.nb.html lab access only

Cohorts included in this study

  • 46 case-control studies: 21,982 cases + 41,944 controls

  • final sample: 94,437 individuals = 35,274 clinical and autopsy-documented AD cases + 59,163 controls

  • 4 consortia (46 case-control studies in Suppl. Table 2) non-Hispanic Whites (NHW):

  • ADGC: Alzheimer Disease Genetics Consortium

  • CHARGE: Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium

  • EADI: The European Alzheimer’s Disease Initiative

  • GERAD/PERADES: Genetic and Environmental Risk in AD/Defining Genetic, Polygenic and Environmental Risk for Alzheimer’s Disease Consortium

Supplementary Table 1. Description of the consortium data sets used for Stage 1 discovery, Stage 2 and Stage 3. Discovery

Alzheimer’s disease casesControls
ConsortiumNPercent femaleMean AAO (s.d)NPercent femaleMean AAE (s.d)
ADGC14,42859.371.1 (17.3)14,56259.376.2 (9.9)
CHARGE2,13767.382.6 (12)13,47455.876.7 (8.2)
EADI2,2406575.4 (9.1)6,63160.678.9 (7.0)
GERAD3,1776473.0 (0.2)7,27751.851.0 (0.1)
N21,98241,944

Stage 2*

CountryNPercent femaleMean AAO (s.d)NPercent femaleMean AAE (s.d.)
Belgium87866.178.8 (8.2)66159.565.7 (14.3)
Finland4226871.4 (6.9)56259.369.1 (6.2)
Germany97263.973.0 (8.6)2,37853.169.5 (10.1)
Greece25663.373.1 (7.9)22934.149.3 (16.4)
Hungary1256878.9 (7.3)1006974.4 (6.5)
Italy1,72966.571.5 (8.7)72055.770.0 (10.4)
Spain2,12166.375.0 (8.3)1,92155.370.2 (10.8)
Sweden79761.776.8 (8.1)1,50662.870.6 (8.7)
UK49067.674.6 (8.7)1,06629.273.8 (6.5)
USA57261.983.5 (7.6)1,3405479.3 (6.8)
N8,36210,483

Stage 3*

CountryNPercent femaleMean AAO (s.d)NPercent femaleMean AAE (s.d.)
Spain (ACE)9327177.7 (7.9)1,81368.454.7 (12.1)
UK (Cardiff)1,90264.877.1 (7.9)1,04757.873.9 (12.9)
USA (ADC7)51451.373.9 (8.3)79063.672.3 (7.7)
Spain (GR@ACE)1,58274.678.5 (8.0)3,0864854.0 (14.0)
N4,9306,736
  • AAO, age at onset; AAE, age at examination.
  • *Stage 2 and Stage 3 datasets were combined for genotyping of 33 replication variants not present on the 2013 custom chip

Supplementary Table 2. Demographic description of datasets within each consortium.

ConsortiumAD casesControls
N% femaleMean AA (SD)N% femaleMean AAE (SD)
ADGCACT53262.678.8 (12.7)1,57155.681.7 (5.9)
ADGCADC11,54954.371.6 (11.0)51259.276.8 (8.8)
ADGCADC272750.861.4 (29.5)15667.975.8 (7.9)
ADGCADC389454.758.6 (32.8)5866372.8 (17.5)
ADGCADC430455.373.4 (7.0)37763.975.7 (8.1)
ADGCADC528653.173.7 (7.0)50565.577.6 (9.0)
ADGCADC621358.273.9 (7.6)33866.674.6 (9.0)
ADGCADNI26842.275.3 (7.1)17340.578.6 (5.5)
ADGCBIOCARD633.373.8 (6.1)11262.568.0 (5.5)
ADGCCHAP276384.8 (7.6)14452.881.8 (6.6)
ADGCEAS944.485.2 (4.9)14141.184.4 (5.2)
ADGCGenADA66656.972.8 (13.5)71263.974.2 (7.0)
ADGCMAYO65857.473.6 (4.8)1,04651.172.9 (4.4)
ADGCMIRAGE49163.369.9 (11.5)73858.870.8 (12.1)
ADGCMTC2565773.6 (11.8)18961.470.9 (9.7)
ADGCNIALOAD1,7986573.1 (9.3)1,56860.273.8 (9.3)
ADGCNBB8071.374.5 (7.5)4856.381.5 (9.4)
ADGCOHSU13262.185.9 (5.7)15354.983.9 (7.6)
ADGCPFIZER69653.773.7 (5.0)76254.177.2 (4.9)
ADGCRMAYO1323.178.5 (9.0)23341.679.2 (5.8)
ADGCROSMAP29570.585.6 (6.2)7697282.2 (7.1)
ADGCROSMAP2597881.9 (6.9)2177680.8 (7.2)
ADGCTARC132361.674.0 (7.1)18165.273.9 (8.2)
ADGCTGEN266864.867.2 (22.9)36548.580.0 (8.7)
ADGCUKS59657.472.2 (6.6)17051.264.1 (3.0)
ADGCUMCWRMSSM1,17764.571.1 (17.4)1,12661.373.5 (10.6)
ADGCUPITT1,25562.966.8 (22.4)82963.375.5 (6.0)
ADGCWASHU33957.269.1 (21.5)18760.476.9 (8.4)
ADGCWASHU23857.973.4 (7.3)9446.851.7 (35.2)
ADGCWHICAP7372.683.9 (7.8)56060.481.7 (6.7)
CHARGEAGES9551.681.5 (0.1)2,70859.275.7 (0.1)
CHARGEASPS27757.876.4 (8.3)1695866.4 (10.8)
CHARGECHS4506681.9 (5.2)1,70260.381.1 (5.2)
CHARGEFHS3306486.1 (7.2)3,9104974.0 (9.5)
CHARGEROTTERDAM98573.283.5 (6.6)4,98557.678.0 (7.6)
EADI2,2406575.4 (9.1)6,63160.678.9 (7.0)
GERAD  MRC1,00870.380.9 (6.5)87361.675.9 (6.3)
GERAD  ARUK9396176.6 (9.6)8259.877.9 (7.6)
GERAD  BONN55163.772.9 (8.3)3764.979.5 (3.6)
GERAD  WASHU4235682.1 (9.0)15665.478.5 (9.7)
GERAD  NIMH1276380.1 (6.1)---
  GERAD UCL:PRION8259.863.6 (9.9)---
  GERAD UCL:LASER4774.580.6(7.9)---
  GERAD 1958BC---5,34249.845.0 (0.0)
GERAD  KORA---43449.156.0 (7.2)
GERAD  HNR---35352.954.6 (5.3)
GERAD  MAYO1------
TOTALS21,98241,944